Protocol
Polypill (statin and blood pressure drugs in one daily pill)
In SECURE, 2,499 people after a heart attack given a polypill (aspirin, ramipril and atorvastatin) had fewer cardiovascular events than with usual care (9.5% against 12.7%, HR 0.76).
At a glance
A polypill puts several heart drugs into one daily pill. It usually has a statin, blood pressure drugs and sometimes aspirin. After a heart attack, people on the polypill had fewer new heart problems than people on their usual pills. In people without heart disease it also helped, but that result was right on the edge.
- What was measured
- Heart attacks, strokes, heart-related deaths and urgent heart procedures.
- How big
- After a heart attack, new heart problems were 9.5% with the polypill against 12.7% with usual care.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 36018037.
- Who it applies to
- Adults after a heart attack, and adults at intermediate risk without heart disease.
- Safety
- The aspirin component raises bleeding risk; pill-specific doses were used in the trials.
- Compared with
- Usual separate medicines (SECURE) or placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received. (TIPS-3).
- Certainty
- Grade B, resting on: Two large randomized trials with hard cardiovascular endpoints The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score., in different populations.
- What would change this grade
- Could rise to A with: Randomized trial of a polypill. Who: Adults without heart disease at intermediate risk, a second population. Measured: Major cardiovascular events. Length: At least 4 years.
- Cost
- No price recorded yet.
- Sources
- 2 studies cited on this record, listed under Sources.
- For clinicians
- A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
In SECURE, 2,499 people after a heart attack given a polypill (aspirin, ramipril and atorvastatin) had fewer cardiovascular events than with usual care (9.5% against 12.7%, HR 0.76). In TIPS-3, 5,713 people without heart disease given a polypill had fewer events than with placebo (4.4% against 5.5%, HR 0.79), with a confidence interval The range the true effect probably falls in. A wide interval means the estimate is uncertain. that reached no effect. The two trials tested different people, so neither replicates the other.
Why this letter
Why this gradeThe reasoning, and what the grade does not cover.
Grade B on major cardiovascular events. After a heart attack, a polypill lowered events against usual care (Castellano et al., 2022; PMID 36018037), and in people without heart disease it lowered events against placebo with an interval reaching no effect (Yusuf et al., 2021; PMID 33186492). SUPPORT: SECURE's result is supported by TIPS-3, an independent trial by a different group in a different population, whose result points the same way.
WHY NOT Athe two trials tested different populations and comparators, so neither replicates the other, and the primary-prevention result is borderline.
WHAT THIS GRADE DOES NOT COVERthe separate drugs taken as separate pills, which are graded on the statin and blood pressure records, and aspirin for primary prevention in healthy older adults, which has its own record and a different answer.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Who responds: this record's trial reading reports no subgroup that identifies who responds.
Evidence notes: randomized trial
Endpoint graded: Major cardiovascular events (hard)
Last reviewed: November 2026
The trial that would change this grade.
Positive trials of this shape from independent research groups would move this entry to A.
Why the current trials fall short
A second primary-prevention trial would supply replication The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away..
ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Drug Combinations among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.
Search recruiting studies of Drug Combinations on ClinicalTrials.gov
Dose, form and timing
Blood pressure, LDL Low-density lipoprotein cholesterol, the cholesterol fraction most closely tied to plaque in the arteries. cholesterol, and bleeding if aspirin is part of the pill.
As studiedDose, form, population and duration for every use.
A grade describes the intervention that was tested. Where the product on the shelf differs from it, this says so.
Safety
No human harm data, with cautions for groups never studied. Each caution on this record, sorted by what it rests on.
None recorded.
None recorded.
None recorded.
- People who bleed easily or take other blood thinners: the aspirin component adds bleeding risk
No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.
Grade history
How this letter has changedLatest: No. 462 · November 2026 · First graded.
New record in the gap-report batch. In SECURE, 2,499 people after a heart attack given a polypill (aspirin, ramipril and atorvastatin) had fewer cardiovascular events than with usual care (9.5% against 12.7%, HR 0.76). In TIPS-3, 5,713 people without heart disease given a polypill had fewer events than with placebo (4.4% against 5.5%, HR 0.79), with a confidence interval that reached no effect. The two trials tested different people, so neither replicates the other.PMID 36018037 PMID 33186492
Every change to a letter on this site is dated and published. The full evidence log →
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
The evidence, in fullTwo papers, each linked to its PubMed record.
Castellano et al. (N Engl J Med, 2022; PMID 36018037): SECURE, 2,499 patients within 6 months of myocardial infarction, polypill against usual care, median 36 months; primary outcome 9.5% against 12.7% (HR 0.76, 95% CI 0.60 to 0.96). Yusuf et al. (N Engl J Med, 2021; PMID 33186492): TIPS-3, 5,713 people at intermediate risk without cardiovascular disease, polypill against placebo, mean 4.6 years; LDL about 19 mg/dL and systolic pressure about 5.8 mmHg lower; primary outcome 4.4% against 5.5% (HR 0.79, 95% CI 0.63 to 1.00).
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
(polypill[tiab] OR "fixed-dose combination"[tiab]) AND cardiovascular[tiab] AND randomized controlled trial[pt]PubMed watch: does a new study change the grade? (nothing new)
No new paper matching the search behind this grade has been added to PubMed since November 2026.
Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.
For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.
- Castellano et al., 2022, N Engl J Med (PMID 36018037): PubMed lists funding from European Union Horizon 2020.
- Yusuf et al., 2021, N Engl J Med (PMID 33186492): PubMed lists funding from Wellcome Trust and others; Wellcome Trust; Wellcome; CIHR.
Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →